

RESOURCE GUIDE

Case Concepts in Generalized Myasthenia Gravis: **Balancing the Need for Glucocorticoids and FcRn Inhibitors**

This handout contains a list of key resources on the management of gMG, including information on steroid toxicities, guideline recommendations, and clinical trial data on FcRn inhibitors.

Guideline Recommendations on the Management of gMG

German Guidelines: Wiendl H, et al. Guideline for the management of myasthenic syndromes. *Ther Adv Neurol Disord*. 2023;16.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752078

International Consensus Guidance: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: executive summary. *Neurology*. 2016;87:419-25.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977114

International Consensus Guidance: Narayanaswami P, et al. International consensus guidance for management of myasthenia gravis: 2020 update. *Neurology*. 2021;96:114-22.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884987

Japanese Guidelines: Murai H, et al. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome. *Clin Exp Neuroimmunol*. 2023;14:19-27.
https://onlinelibrary.wiley.com/doi/full/10.1111/cen3.12739

Glucocorticoid Toxicity Index Tool

Stone JH, et al. The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time [published correction appears in *Semin Arthritis Rheum*. 2023;58:152124]. *Semin Arthritis Rheum*. 2022;55:152010.
https://www.sciencedirect.com/science/article/pii/S0049017222000610?via%3Dihub

FcRn Inhibitors: Phase 3 Clinical Trial Publications

Rozanolixizumab: Bril V, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study [published correction appears in *Lancet Neurol*. 2023;22):e11]. *Lancet Neurol*. 2023;22:383-94.
https://pubmed.ncbi.nlm.nih.gov/37059507
(not open access)

Efgartigimod: Howard JF Jr, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial [published correction appears in *Lancet Neurol*. 2021;20:e5]. *Lancet Neurol*. 2021;20:526-36.
https://pubmed.ncbi.nlm.nih.gov/34146511
(not open access)

Efgartigimod: Sacca F, et al. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT). *J Neurol*. 2023;270:2096-105.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025199/

FcRn Inhibitors: Reviews

Bhandari V, et al. FcRN receptor antagonists in the management of myasthenia gravis. *Front Neurol*. 2023;14:1229112.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439012

Gable KL, et al. Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. *Front Immunol*. 2020;10:3052.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965493

Glucocorticoid Therapy and Monitoring

Fardet L, et al. Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study. *Medicine (Baltimore)*. 2015;94:e647.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602514

Johnson S, et al. Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis. *Med Sci Monit*. 2021;27:e933296-1.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562011

Liu D, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy Asthma Clin Immunol*. 2013;9:30.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765115

Provided by

Med-IQ®